Barcelona, Spain—People with celiac disease may soon be able to have their gluten-rich cake and eat it, too.
In a phase 2 trial presented at the 2019 United European Gastroenterology Week, a first-of-its-kind drug significantly dampened the immune activation and reduced the intestinal damage that people with celiac disease experience in response to gluten.
“If our findings are confirmed by subsequent studies, this treatment may represent a revolutionary change in how we manage celiac